Comparative Study between Nifedipine and Isoxsuprine in Suppression of Preterm Labour

Authors

  • Loai Hasan Tishreen Journal
  • Lina Ramadan
  • Hazar Khadora

Abstract

Background: Preterm labor is a cause of high rates of perinatal morbidity and mortality. The use of tocolytics is one of the efforts to handle the risk of preterm labor.

Aim: The purpose of the study was to compare the efficacy of nifedipine against isoxsuprine in inhibiting preterm labour and also to evaluate maternal side effects and neonatal outcome.

Materials and Methods: This randomized prospective study comprised of 92 patients with preterm labor with a gestational age between 24 – 36 weeks, admitted to Department of Obstetrics and Gynecology, Tishreen university Hospital, Lattakia, Syria, during the period of November 2018 to November 2019. The Patients who fullfield the inclusion criteria for the study were divided into 2 groups; the first consisted of 58 patients, treated with Nifedipine for tocolysis, the second consisted of 34 patients, who received isoxsuprine for tocolysis. Patients were monitored throughout the course of treatment and followed until delivery.

Results: Baseline characteristics were well matched in both study groups. Mean prolongation of pregnancy was 31.6 days in Nifedipine and 22.9 days in Isoxsuprine group which was statistically significant. Success rate with Nifedipine was found to be 84.5% as compared to Isoxsuprine which was 70.5%.  Maternal side effects like tachycardia (38.2%) and hypotension (14.7%) were common in Isoxsuprine group, while headache (51.7%) and facial flushing (56.9%) were common in Nifedipine group. The mean neonatal weight in Isoxsuprine group (2.07kg) was lower than Nifedipine group (2.38kg), with no differences in Apgar score between the two groups. The Cervical dilatation when applying the treatment had shown a significant relationship with the success of tocolysis in both drugs.

Conclusion: Nifedipine is a better tolerated, more effective and safe tocolytic agent than Isoxsuprine with few maternal complications.

Downloads

Published

2020-10-01

How to Cite

1.
حسن ل, رمضان ل, خضورة ه. Comparative Study between Nifedipine and Isoxsuprine in Suppression of Preterm Labour. Tuj-hlth [Internet]. 2020Oct.1 [cited 2024Nov.24];42(4). Available from: https://journal.tishreen.edu.sy/index.php/hlthscnc/article/view/9856

Issue

Vol. 42 No. 4 (2020): Tishreen University Journal for Research and Scientific Studies - Medical Sciences Series

Section

Articles

License

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

The authors retain the copyright and grant the right to publish in the magazine for the first time with the transfer of the commercial right to Tishreen University Journal for Research and Scientific Studies - Health Sciences Series

 Under a CC BY- NC-SA 04 license that allows others to share the work with of the work's authorship and initial publication in this journal. Authors can use a copy of their articles in their scientific activity, and on their scientific websites, provided that the place of publication is indicted in  Tishreen University Journal for Research and Scientific Studies - Health Sciences Series   .  The Readers have the right to send, print and subscribe to the initial version of the article, and the title of  Tishreen University Journal for Research and Scientific Studies - Health Sciences Series  Publisher

journal uses a CC BY-NC-SA license which mean

You are free to:

  • Adapt — remix, transform, and build upon the material
  •  
  • The licensor cannot revoke these freedoms as long as you follow the license terms.

 

  • Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
  • NonCommercial — You may not use the material for commercial purposes.
  • ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
  • No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

Most read articles by the same author(s)

<< < 1 2